- Report
- April 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 240 Pages
Global
From €2372EUR$2,690USD£2,054GBP
- Report
- July 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- March 2025
- 150 Pages
Global
From €3395EUR$3,850USD£2,939GBP
€4277EUR$4,850USD£3,703GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1102EUR$1,250USD£954GBP
- Report
- September 2025
- 485 Pages
Global
From €5159EUR$5,850USD£4,466GBP
- Report
- September 2025
- 483 Pages
Global
From €5159EUR$5,850USD£4,466GBP
- Report
- September 2025
- 377 Pages
Global
From €5159EUR$5,850USD£4,466GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2205EUR$2,500USD£1,909GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2460EUR$2,789USD£2,129GBP
- Report
- June 2025
- 200 Pages
United States
From €2196EUR$2,490USD£1,901GBP
- Report
- August 2022
- 115 Pages
Global
From €3969EUR$4,500USD£3,436GBP
- Report
- August 2024
- 233 Pages
Global
From €7011EUR$7,950USD£6,070GBP
- Report
- January 2024
- 395 Pages
Global
From €6614EUR$7,500USD£5,726GBP
- Report
- May 2024
- 135 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- May 2024
- 132 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- May 2024
- 138 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- May 2024
- 128 Pages
Global
From €5732EUR$6,499USD£4,962GBP
- Report
- June 2024
- 185 Pages
Global
From €3969EUR$4,500USD£3,436GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more